Literature DB >> 32664053

Protective effect of anthrax toxin receptor 2 polymorphism rs4333130 against the risk of ankylosing spondylitis.

Haitao Xu1, Yiming Qu.   

Abstract

BACKGROUND: The present study was performed to statistically explore the effect of anthrax toxin receptor 2 (ANTXR2) polymorphism rs4333130 on individual susceptibility to ankylosing spondylitis (AS) using the method of meta-analysis.
METHODS: All of the eligible reports were retrieved from well-known electronic databases. The strength of the association between ANTXR2 polymorphism rs4333130 and the susceptibility to AS was evaluated using pooled odds ratios (ORs) with 95% confidence intervals (95% CIs). In addition, subgroup analysis was also performed on the basis of ethnicity to further explore specific correlation between our studied polymorphism and the disease risk. Inter-study heterogeneity was detected with Q test, and P < .05 was considered statistically significant. Sensitivity analysis was implemented through removing each of eligible studies and then recalculating overall effects to test the reliability of final estimates. Publication bias among included studies was inspected with both Begg funnel plot and Egger regression test.
RESULTS: A total of 6 eligible papers were finally incorporated into the present meta-analysis. In total analysis, ANTXR2 polymorphism rs4333130 was significantly related to decreased risk of AS under CC versus TT, CC + TC versus TT, CC versus TT + TC, C versus T and TC versus TT contrasts (OR = 0.35, 95% CI = 0.20-0.64; OR = 0.81, 95% CI = 0.69-0.95; OR = 0.38, 95% CI = 0.21-0.68; OR = 0.89, 95% CI = 0.84-0.95; OR = 0.84, 95% CI = 0.72-0.99). Moreover, a similar effect was also observed in Asian and Caucasian subgroups under corresponding genetic models after stratification analysis based on ethnicity.
CONCLUSION: ANTXR2 polymorphism rs4333130 may function as a protective factor against AS incidence.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32664053      PMCID: PMC7360223          DOI: 10.1097/MD.0000000000019942

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


Introduction

Ankylosing spondylitis (AS) is a common disease with high disability rate. The prevalence of this disease is about 0.1% to 1.4% all over the world, which reaches approximately 0.23% in China.[ With rapid progression, AS generally attacks young people, and exhibits poor prognosis when treatments are delayed or inappropriate.[ In AS patients, the most common clinical symptom is back pain which is featured by morning stiffness and alleviation after exercises.[ The sign of this disease is acute and chronic inflammations at sacroiliac joint and at the points of tendons and ligaments attaching to the bone.[ In most cases, AS first attacks sacroiliac joint, and then involves axial skeleton. Besides, peripheral joints are also involved in different degrees for certain patients, especially the hip and knee.[ Long-term chronic inflammation will eventually lead to complete fusion of vertebral column and/or peripheral joints as well as the loss of activity.[ The exact pathogenesis of AS has not been totally understood, but it has been universally established that the disease susceptibility greatly depends on genetic factors.[ Anthrax toxin contains 3 protein subunits, namely protective antigen (PA), lethal factor, and edema factor.[ These proteins are non-toxic when they exist in isolation, but they can aggregate on cells’ surface to form a toxic complex, with PA as the central part. There are 2 known cell surface receptors for PA, namely anthrax toxin receptor 1 (ANTXR1) and ANTXR2, both of which can express in multiple human tissues.[ ANTXR2, a capillary morphogenesis protein, is first expressed when capillary forms. This transmembrane protein can bind with laminins and type IV collagen,[ thus expressing widely in heart, lung, liver, skeletal muscle, peripheral leucocytes, placenta, small intestine, kidney, colon, and spleen. An earlier genome-wide association study among Europeans has reported that the coding gene for this protein is closely related to AS onset.[ In the past several years, some scholars have focused on the relationships of AS with ANTXR2 gene polymorphisms. Thereinto, rs4333130 is the one studied most commonly. Although the number of previous studies on AS susceptibility and ANTXR2 polymorphism rs4333130 is not too much, they still fail to reach uniform findings on this relationship. Therefore, we performed the present meta-analysis based on available publications to pool relevant findings for a clearer perspective on this issue.

Materials and methods

Literature search strategy

We systemically searched the electronic databases of PubMed, EMBASE, Cochrane Library, Google Scholar Web, ISI Web of Science, Chinese National Knowledge Infrastructure, and Wanfang, adopting the combination of the following key terms: “ankylosing spondylitis or Bechterew's disease,” “anthrax toxin receptor 2 or ANTXR2 or capillary morphogenesis gene-2 or CMG2,” and “polymorphism or variation or variant or mutation.” No restrictions were imposed on publication year, ethnic descent, or sample size. In addition, the references of all relevant articles were also manually screened for additional publications.

Selection criteria

In advance, we formulated a series of criteria for selecting eligible studies: published in English or Chinese language; enrolling human beings as study subjects; focusing on ANTXR2 polymorphism rs4333130 and the susceptibility to AS; containing both case and control groups; and providing enough information about genotype and allele frequencies in the 2 groups. Therefore, publications not fulfilling any one of those standards were deleted. Besides, letters, duplicates, comments, and case reports were all removed from the present meta-analysis.

Data extraction

Using a standardized data sheet, 2 reviewers independently extracted primary information from all eligible studies, and implemented cross-check over these data to ensure their accuracy. Any discrepancies occurred over these data would be settled through discussion between the 2 reviewers to reach a consensus. Recorded information on the sheet included the name of the first author, publication year, ethnic line, genotyping method, numbers of cases and controls, genotype and allele distribution in the 2 groups, P-value for Hardy–Weinberg equilibrium in controls, and human leukocyte antigen (HLA)-B27 status in 2 groups.

Statistical analysis

STATA 12.0 software (Stata Corporation, College Station, TX) was employed for all data syntheses in the present meta-analysis, and the significance level was set at P < .05 for all tests. The intensity of the relationship between ANTXR2 polymorphism rs4333130 and individual susceptibility to AS was appraised through pooling summarized odds ratios (ORs) with their corresponding 95% confidence intervals (95% CIs) under all 5 genetic models: CC versus TT, CC + TC versus TT, CC versus TT + TC, C versus T and TC versus TT. Hardy–Weinberg equilibrium in the controls was determined by Chi-square test. Besides, subgroup analysis based on ethnicity was also performed to further explore potential specific relationship. Heterogeneity among included studies was detected using Chi-square-based Q test, with P-value less than .05 as significant level. When inter-study heterogeneity was significant, random-effects model would be selected for assessing overall estimates; otherwise, fixed-effects model would be applied. Sensitivity analysis was implemented via removing each of included studies sequentially and recalculating overall ORs so as to detect the stability of final effects. Begg funnel plot and Egger regression test were utilized to investigate potential publication bias between included studies.

Results

Searching outcomes and study characteristics

Literature searching in the electronic databases initially identified 65 potentially relevant articles, and 18 of them were first deleted for duplicates (Fig. 1). Next, 28 more reports were removed for obvious irrelevancy. And additional 13 papers were eliminated in further evaluation due to involving other diseases (3), reviews (2), concerning other polymorphisms (6), and exploring AS treatment (2). Consequently, 6 qualified publications from 2010 to 2016 were ultimately embraced in the current meta-analysis, containing a total of 5589 case and 10,742 controls.[ Among these studies, 5 focused on Asian populations while only 1 referred to Caucasians. As for HLA-B27 status, only 2 articles offered exact numbers of cases and controls, while others only displayed incomplete information or did not provide at all. Table 1 lists more detailed information about the included studies.
Figure 1

Flowchart for literature search and selection.

Table 1

Essential information of eligible studies in the meta-analysis.

Flowchart for literature search and selection. Essential information of eligible studies in the meta-analysis.

Quantitative data synthesis

As shown in Table 2, ANTXR2 polymorphism rs4333130 significantly reduced the risk of developing AS in total analysis under all 5 genetic models of CC versus TT, CC + TC versus TT, CC versus TT + TC, C versus T (Fig. 2) and TC versus TT (OR = 0.35, 95% CI = 0.20–0.64; OR = 0.81, 95% CI = 0.69–0.95; OR = 0.38, 95% CI = 0.21–0.68; OR = 0.89, 95% CI = 0.84–0.95; OR = 0.84, 95% CI = 0.72–0.99). Moreover, such a downward tendency was also detected in Asians and Caucasians under corresponding comparisons after subgroup analysis on the basis of ethnicity (Fig. 2).
Table 2

Relationship between ANTXR2 polymorphism rs4333130 and the susceptibility to ankylosing spondylitis.

Figure 2

Forest plot for the association between ANTXR2 polymorphism rs4333130 and the risk of ankylosing spondylitis under C versus T contrast by ethnicity. ANTXR2 = anthrax toxin receptor 2.

Relationship between ANTXR2 polymorphism rs4333130 and the susceptibility to ankylosing spondylitis. Forest plot for the association between ANTXR2 polymorphism rs4333130 and the risk of ankylosing spondylitis under C versus T contrast by ethnicity. ANTXR2 = anthrax toxin receptor 2.

Heterogeneity test and sensitivity analysis

P-values from Q test were more than .05 under all contrasts, demonstrating the lack of statistical significance for inter-study heterogeneity, so the fixed-effects model was chosen for OR calculations in this work. According to the results from sensitivity analysis, none of recalculated ORs had substantial differences from original ones (Fig. 3), indicating that our findings were stable and reliable.
Figure 3

Sensitivity analysis testing the reliability of final estimate.

Sensitivity analysis testing the reliability of final estimate.

Publication bias examination

Funnel plots displayed fine symmetry (Fig. 4), and statistical data from Egger test further supported such judgment (C vs T: P = .660). Therefore, publication bias between included studies was negligible in the present meta-analysis.
Figure 4

Begg funnel plot of potential publication bias (model: C vs T).

Begg funnel plot of potential publication bias (model: C vs T).

Discussion

AS is a chronic inflammatory disease mainly invading sacroiliac joint and vertebral column, with unclear pathogenic mechanism. Until now, no effective therapeutic measures have been developed for this disease yet. HLA-B27 belongs to major histocompatibility complex gene, and represents the most well known gene related to AS susceptibility.[ According to relevant records, HLA-B27 is positive among the vast majority of AS patients, but only a small part of HLA-B27-positive individuals will eventually develop this disease, indicating that other genes than HLA may also play critical roles in the disease incidence.[ The gene ANTXR2 has been proposed to be able to impact AS susceptibility, and a polymorphism in this gene, rs4333130, has been regarded as the target in such researches as well. However, studies on this topic obtain inconsistent findings. For example, Momenzadeh et al found a protective effect of the C allele and CC genotype of ANTXR2 polymorphism rs4333130 against AS occurrence in their research (P = .0328, OR = 0.744, 95% CI = 0.598–0.927; P = .0108, OR = 0.273, 95% CI = 0.123–0.605).[ Such a tendency was also observed in the study by Zhang, with an OR of 0.63 (95% CI = 0.43–0.91, P = .012).[ Nonetheless, Guo et al detected no significant differences in genotype or allele frequencies of this polymorphism between AS cases and controls.[ Moreover, Chen et al reported that this polymorphism had no significant impact on AS risk in Chinese Han population.[ We hypothesized that the discrepancies in those findings between individual studies might be attributed to multiple aspects, including but not limited to different genetic backgrounds, participants’ characteristics, and uneven sample sizes. To strengthen the statistical power of conclusion on the relationship between ANTXR2 polymorphism rs4333130 and AS risk, we carried out this meta-analysis through analyzing the findings from all available relevant papers. After literature search and selection, we totally obtained 6 eligible publications for our meta-analysis, enrolling 5589 case and 10,742 controls. According to synthesized data, ANTXR2 polymorphism rs4333130 was related to reduced risk of developing AS in total analysis under CC versus TT, CC + TC versus TT, CC versus TT + TC, C versus T and TC versus TT genetic models; such an effect was also detected in Asian and Caucasian subgroups after stratification analysis by ethnicity. These findings indicated that the polymorphism rs4333130 might offer protection against AS incidence. Q test revealed no significant heterogeneity among included studies, so overall estimates in this work were pooled using the fixed-effects model. In sensitivity analysis, re-obtained ORs showed no substantial differences from original ones, providing evidence for the stability of final effects. In addition, both funnel plot and Egger test demonstrated that publication bias between eligible studies was negligible, possibly possessing little impact on our findings, which further guaranteed the robustness of our conclusion. That was in accordance with previous meta-analysis study.[ That being said, our findings still should be interpreted with prudence due to some inevitable restrictions in the present work. First, the number of included studies was relatively small, which reduced the comprehensiveness of our findings. Second, we only searched several electronic databases for eligible articles published in English or Chinese language, and some pertinent reports in other sources or languages might be missed, thus introducing certain publication bias, though not significant. Third, detailed subgroup analyses on other possibly relevant factors were not carried out in this work owing to limited information from original papers. For example, HLA-B27 status represents a key effector on AS risk, but our included studies did not precisely stated genotype and/or allele distribution in cases and controls stratified by this element, so we failed to complete stratification analysis according to this factor. Last but not the least, potential effects of gene-gene and gene-environment interactions on AS susceptibility were neglected in our study. In conclusion, ANTXR2 polymorphism rs4333130 may exert a protective effect against developing AS. Nevertheless, in view of the above mentioned shortcomings in the present meta-analysis, our findings need to be further verified by studies with larger sample sizes and more considerations of other factors possibly related to AS risk.

Author contributions

H.X. conceived and designed the experiments; Y.Q. analyzed the data, and wrote the paper; H.X., Y.Q. performed the experiments. All authors read and approved the final manuscript.
  26 in total

1.  Anthrax toxin receptor 2 gene (ANTXR2) rs4333130 is associated with ankylosing spondylitis.

Authors:  Yanjuan Ou
Journal:  Int J Clin Exp Med       Date:  2015-05-15

2.  Genetic studies of ankylosing spondylitis in Koreans confirm associations with ERAP1 and 2p15 reported in white patients.

Authors:  So-Young Bang; Tae-Hwan Kim; Bitnara Lee; Eunji Kwon; Sang Hyun Choi; Ki Soo Lee; Seung Cheol Shim; Angela Pope; Proton Rahman; John D Reveille; Robert D Inman
Journal:  J Rheumatol       Date:  2010-11-01       Impact factor: 4.666

3.  ANTXR2 and IL-1R2 polymorphisms are not associated with ankylosing spondylitis in Chinese Han population.

Authors:  Chao Chen; Xuesong Zhang; Yan Wang
Journal:  Rheumatol Int       Date:  2010-07-21       Impact factor: 2.631

4.  Determination of IL1 R2, ANTXR2, CARD9, and SNAPC4 single nucleotide polymorphisms in Iranian patients with ankylosing spondylitis.

Authors:  Parisa Momenzadeh; Mahdi Mahmoudi; Maani Beigy; Masoud Garshasbi; Mahdi Vodjdanian; Ali Farazmand; Ahmad Reza Jamshidi
Journal:  Rheumatol Int       Date:  2015-11-21       Impact factor: 2.631

5.  Targeted silencing of anthrax toxin receptors protects against anthrax toxins.

Authors:  Maria T Arévalo; Ashley Navarro; Chenoa D Arico; Junwei Li; Omar Alkhatib; Shan Chen; Diana Diaz-Arévalo; Mingtao Zeng
Journal:  J Biol Chem       Date:  2014-04-17       Impact factor: 5.157

Review 6.  Construct validity of clinical spinal mobility tests in ankylosing spondylitis: a systematic review and meta-analysis.

Authors:  Marcelo P Castro; Simon M Stebbings; Stephan Milosavljevic; Melanie D Bussey
Journal:  Clin Rheumatol       Date:  2015-09-04       Impact factor: 2.980

7.  Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1.

Authors:  Adrian Cortes; Sara L Pulit; Paul J Leo; Jenny J Pointon; Philip C Robinson; Michael H Weisman; Michael Ward; Lianne S Gensler; Xiaodong Zhou; Henri-Jean Garchon; Gilles Chiocchia; Johannes Nossent; Benedicte A Lie; Øystein Førre; Jaakko Tuomilehto; Kari Laiho; Linda A Bradbury; Dirk Elewaut; Ruben Burgos-Vargas; Simon Stebbings; Louise Appleton; Claire Farrah; Jonathan Lau; Nigil Haroon; Juan Mulero; Francisco J Blanco; Miguel A Gonzalez-Gay; C Lopez-Larrea; Paul Bowness; Karl Gaffney; Hill Gaston; Dafna D Gladman; Proton Rahman; Walter P Maksymowych; J Bart A Crusius; Irene E van der Horst-Bruinsma; Raphael Valle-Oñate; Consuelo Romero-Sánchez; Inger Myrnes Hansen; Fernando M Pimentel-Santos; Robert D Inman; Javier Martin; Maxime Breban; Bryan Paul Wordsworth; John D Reveille; David M Evans; Paul I W de Bakker; Matthew A Brown
Journal:  Nat Commun       Date:  2015-05-21       Impact factor: 14.919

8.  Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci.

Authors:  John D Reveille; Anne-Marie Sims; Patrick Danoy; David M Evans; Paul Leo; Jennifer J Pointon; Rui Jin; Xiaodong Zhou; Linda A Bradbury; Louise H Appleton; John C Davis; Laura Diekman; Tracey Doan; Alison Dowling; Ran Duan; Emma L Duncan; Claire Farrar; Johanna Hadler; David Harvey; Tugce Karaderi; Rebecca Mogg; Emma Pomeroy; Karena Pryce; Jacqueline Taylor; Laurie Savage; Panos Deloukas; Vasudev Kumanduri; Leena Peltonen; Sue M Ring; Pamela Whittaker; Evgeny Glazov; Gethin P Thomas; Walter P Maksymowych; Robert D Inman; Michael M Ward; Millicent A Stone; Michael H Weisman; B Paul Wordsworth; Matthew A Brown
Journal:  Nat Genet       Date:  2010-01-10       Impact factor: 38.330

9.  Biologic Treatment Registry Across Canada (BioTRAC): a multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitis.

Authors:  Proton Rahman; Denis Choquette; William G Bensen; Majed Khraishi; Andrew Chow; Michel Zummer; Saeed Shaikh; Maqbool Sheriff; Sanjay Dixit; Dalton Sholter; Eliofotisti Psaradellis; John S Sampalis; Vincent Letourneau; Allen J Lehman; François Nantel; Emmanouil Rampakakis; Susan Otawa; May Shawi
Journal:  BMJ Open       Date:  2016-04-05       Impact factor: 2.692

Review 10.  Tumor Targeting and Drug Delivery by Anthrax Toxin.

Authors:  Christopher Bachran; Stephen H Leppla
Journal:  Toxins (Basel)       Date:  2016-07-01       Impact factor: 4.546

View more
  1 in total

1.  The effect of electronic moxibustion combined with rehabilitation nursing on the lumbar pain and stiffness of ankylosing spondylitis patients.

Authors:  Xin Huan; Liugeng Wu; Meiyi Wang; Danping Xue; Feng Tian
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.